(Q37082119)

18 August 2017

1 reference

title

SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease (English)

1 reference

18 August 2017

1 reference

1 reference

Jan Booij

1

1 reference

PubMed ID

18267276

18 August 2017

Remco J J Knol

series ordinal

2

1 reference

PubMed ID

18267276

18 August 2017

language of work or name

1 reference

1 January 2007

1 reference

Parkinsonism and Related Disorders

18 August 2017

1 reference

18 August 2017

13 Suppl 3

1 reference

18 August 2017

S425-8

1 reference

Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism.

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

Midbrain dopamine D2/3 receptor binding in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

Levodopa and the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. Baseline and 3‐month observations

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

Idiopathic hyposmia as a preclinical sign of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

The role of radiotracer imaging in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2808%2970042-7

7 January 2021

10.1016/S1353-8020(08)70042-7

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18267276